Compare Liquidia Corporation Common Stock (LQDA) vs Medline Inc. Class A Common Stock (MDLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liquidia Corporation Common Stock vs Medline Inc. Class A Common Stock — how do they compare? Liquidia Corporation Common Stock trades at $33.75 (market cap $2.40B), while Medline Inc. Class A Common Stock trades at $35.85 (market cap $31.32B). The key difference: Medline Inc. Class A Common Stock is far larger — about 13.1× Liquidia Corporation Common Stock's market cap, and Medline Inc. Class A Common Stock is more actively traded (4,364,703 versus 2,857,547). Which is the better fit depends on your goals — on Pluang, investors hold Liquidia Corporation Common Stock for 0 Days and Medline Inc. Class A Common Stock for 6 Days on average.
| LQDA | MDLN | |
|---|---|---|
Market Cap | $2.40B | $31.32B |
Volume | 2,857,547 | 4,364,703 |
Sector | Health | Health |
52-Week High | $91.03 | $49.99 |
52-Week Low | $22.02 | $31.64 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $2.30B | $41.28B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Medline (MDLN) trades at $35.70, down 0.17% with a bullish technical outlook despite recent volatility. The company shows strong revenue growth with $28.43B in 2025 and improved earnings beats in Q1-Q2 2026. However, multiple securities fraud investigations related to product quality issues and a 13% stock drop in October 2026 create significant headwinds. Analyst consensus remains strongly bullish with 88% buy ratings and a $44.11 price target, representing 23.6% upside potential from current levels.
MDLN presents a high-risk, high-reward opportunity with strong fundamentals offset by legal uncertainties. The stock's valuation appears reasonable with P/E of 44.66 and P/S of 1.05, while technical indicators suggest near-term support at $35. Key risks include ongoing fraud investigations and potential legal liabilities that could impact future performance despite positive earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Liquidia Corporation Common Stock
Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →About Medline Inc. Class A Common Stock
Medline provides medical-surgical products and supply-chain solutions for healthcare providers. Its portfolio and distribution network serve hospitals, clinics, long-term care facilities, and other care settings.
Read more on MDLN →
